Exelixis, Inc. (NASDAQ:EXEL) Director Sells 12,210 Shares

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Exelixis Trading Up 5.0 %

NASDAQ:EXEL traded up $1.76 during trading hours on Friday, hitting $36.85. 3,489,848 shares of the company were exchanged, compared to its average volume of 2,627,186. The stock has a market capitalization of $10.31 billion, a price-to-earnings ratio of 20.82, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a one year low of $20.14 and a one year high of $37.59. The company has a fifty day simple moving average of $34.16 and a 200 day simple moving average of $31.14.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Oppenheimer lowered Exelixis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $41.00 to $33.00 in a research note on Friday, January 24th. BMO Capital Markets lowered Exelixis from an "outperform" rating to a "market perform" rating and raised their price objective for the company from $36.00 to $40.00 in a research note on Friday, December 20th. JMP Securities reissued a "market outperform" rating and set a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. Guggenheim reissued a "buy" rating and issued a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Finally, Barclays lifted their price target on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and an average price target of $37.24.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Forum Financial Management LP acquired a new stake in shares of Exelixis during the fourth quarter worth $241,000. GF Fund Management CO. LTD. bought a new stake in Exelixis during the fourth quarter valued at $200,000. Neo Ivy Capital Management grew its holdings in Exelixis by 427.8% during the 4th quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company's stock worth $1,794,000 after acquiring an additional 43,682 shares during the period. JT Stratford LLC acquired a new stake in Exelixis during the 4th quarter worth about $288,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Exelixis by 4.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company's stock worth $28,117,000 after acquiring an additional 33,804 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.